CGTX
Cognition Therapeutics Inc

3,942
Mkt Cap
$94.45M
Volume
636,472.00
52W High
$3.83
52W Low
$0.2223
PE Ratio
-2.25
CGTX Fundamentals
Price
$1.07
Prev Close
$1.08
Open
$1.08
50D MA
$1.17
Beta
1.50
Avg. Volume
740,022.89
EPS (Annual)
-$0.855
P/B
2.59
Rev/Employee
$0.00
$3.39
Loading...
Loading...
News
all
press releases
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five brokerages that are currently covering the...
MarketBeat·20d ago
News Placeholder
More News
News Placeholder
FY2025 Earnings Forecast for CGTX Issued By Brookline Cap M
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Investment analysts at Brookline Cap M issued their FY2025 EPS estimates for Cognition Therapeutics in a research note issued to investors...
MarketBeat·1mo ago
News Placeholder
Cognition Therapeutics (NASDAQ:CGTX) Upgraded to Strong-Buy at Brookline Cap M
Brookline Cap M raised shares of Cognition Therapeutics to a "strong-buy" rating in a research report on Tuesday...
MarketBeat·1mo ago
News Placeholder
Brookline Capital Management Predicts CGTX FY2025 Earnings
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Brookline Capital Management issued their FY2025 earnings estimates for shares of Cognition Therapeutics in a research report issued on...
MarketBeat·1mo ago
News Placeholder
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) have earned an average rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat...
MarketBeat·2mo ago
News Placeholder
Cognition Therapeutics (NASDAQ:CGTX) Raised to "Strong-Buy" at Brookline Capital Management
Brookline Capital Management raised shares of Cognition Therapeutics to a "strong-buy" rating in a research report on Tuesday...
MarketBeat·2mo ago
News Placeholder
DAVENPORT & Co LLC Makes New Investment in Cognition Therapeutics, Inc. $CGTX
DAVENPORT & Co LLC purchased a new stake in Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 2,689,336...
MarketBeat·3mo ago
News Placeholder
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five brokerages that are currently covering the firm...
MarketBeat·3mo ago
News Placeholder
Cognition Therapeutics (NASDAQ:CGTX) Earns "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $3.00 price objective on shares of Cognition Therapeutics in a research report on Thursday...
MarketBeat·4mo ago
News Placeholder
Q1 Earnings Forecast for CGTX Issued By B. Riley
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Equities research analysts at B. Riley issued their Q1 2026 earnings per share estimates for Cognition Therapeutics in a report issued on...
MarketBeat·4mo ago
<
1
2
...
>

Latest CGTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.